Enhanced drug delivery in transdermal systems
AssigneeNoven Pharmaceuticals, Inc.
InventorDavid Houze
Life of this patent
Estimating the term…
Abstract
A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.
Claims31
A composition for the transdermal delivery of a drug resulting from an admixture comprising:
- a therapeutically effective amount of a drug that includes a steroid and a corresponding steroid derivative that provides a source of therapeutically active steroid;
- and
- and a pharmaceutically acceptable carrier, wherein the steroid and the corresponding steroid derivative are present in a weight/weight ratio of 10:1 to 1:10 steroid:
- corresponding steroid derivative.
A method for enhancing the transdermal delivery of a drug, comprising administering the drug in a pharmaceutically acceptable carrier that comprises a combination of:
- a therapeutically effective amount of at least one steroid;
- and
- a corresponding steroid derivative that provides a source of therapeutically active steroid, wherein the steroid and the corresponding steroid derivative are present in a weight/weight ratio of 10:1 to 1:10 steroid:
- corresponding steroid derivative.
A method of suppressing crystal formation of a steroid in a transdermal drug delivery system comprising the step of combining two or more corresponding derivatives of the steroid in a pressure-sensitive adhesive carrier composition.
A composition for the transdermal delivery of a drug resulting from an admixture comprising:
- a therapeutically effective amount of a drug that includes norethindrone and norethindrone acetate;
- and
- a pharmaceutically acceptable carrier, wherein the norethindrone and norethindrone acetate steroid are present in a weight/weight ratio of 1:6 to 6:1.
A composition for the transdermal delivery of a drug resulting from an admixture comprising:
- a therapeutically effective amount of a drug that includes norethindrone and norethindrone acetate and estradiol;
- and
- and a pharmaceutically acceptable carrier, wherein the norethindrone and norethindrone acetate are present in a weight/weight ratio of 1:1 to 1:3.
A composition for the transdermal delivery of a drug formed by a process comprising mixing:
- a therapeutically effective amount of a drug that includes a steroid and a corresponding steroid derivative that provides a source of therapeutically active steroid;
- and a pharmaceutically acceptable carrier, wherein the steroid and the corresponding steroid derivative are present in a weight/weight ratio of 10:1 to 1:10 steroid:
- corresponding steroid derivative.
Dependencies are inferred from the claim text.